CD8A and neoplasm: A vaccine that combines the CD8+ T cell chemoattractive properties of pDCs with the superior tumor-antigen specific T cell priming capacity of cDC2s [305] was tested in patients with prostate cancer (NCT02692976), metastatic endometrial cancer (NCT04212377), castration-resistant prostate cancer (CRPC; NCT02692976), and metastatic endometrial cancer (NCT04212377).